| scholarly article | Q13442814 |
| P2093 | author name string | U Schmidt | |
| D Lebeche | |||
| R J Hajjar | |||
| E Williams | |||
| J K Gwathmey | |||
| A Rosenzweig | |||
| F del Monte | |||
| E D Lewandowski | |||
| P2860 | cites work | Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a | Q22010899 |
| A simplified system for generating recombinant adenoviruses | Q24682328 | ||
| Prospects for gene therapy for heart failure | Q33881236 | ||
| Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure | Q34978011 | ||
| Modulation of ventricular function through gene transfer in vivo | Q36067860 | ||
| Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts | Q36835427 | ||
| Relationship between Na+-Ca2+-exchanger protein levels and diastolic function of failing human myocardium | Q48749719 | ||
| Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). | Q53344976 | ||
| Calcineurin and human heart failure | Q56877814 | ||
| Efficient gene transfer into myocardium by direct injection of adenovirus vectors | Q64377591 | ||
| Sarcoplasmic reticulum. XVII. The turnover of proteins and phospholipids in sarcoplasmic reticulum membranes. | Q64907088 | ||
| Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure | Q69122833 | ||
| Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance | Q71056599 | ||
| Unchanged Protein Levels of SERCA II and Phospholamban but Reduced Ca 2+ Uptake and Ca 2+ -ATPase Activity of Cardiac Sarcoplasmic Reticulum From Dilated Cardiomyopathy Patients Compared With Patients With Nonfailing Hearts | Q71807622 | ||
| Cardiac responses to induced lactate oxidation: NMR analysis of metabolic equilibria | Q71949615 | ||
| Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy | Q73804332 | ||
| P(i) inhibits the SR Ca(2+) pump and stimulates pump-mediated Ca(2+) leak in rabbit cardiac myocytes | Q74103780 | ||
| Reduced Ca(2+)-sensitivity of SERCA 2a in failing human myocardium due to reduced serin-16 phospholamban phosphorylation | Q77306347 | ||
| Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure | Q77502354 | ||
| Thermodynamic limitation for Ca2+ handling contributes to decreased contractile reserve in rat hearts | Q77649649 | ||
| Inotropic therapy for heart failure | Q77685831 | ||
| Human heart failure: cAMP stimulation of SR Ca(2+)-ATPase activity and phosphorylation level of phospholamban | Q78117391 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| P304 | page(s) | 1424-9 | |
| P577 | publication date | 2001-09-18 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure | |
| P478 | volume | 104 |
| Q36177187 | A Decoy Peptide Targeted to Protein Phosphatase 1 Attenuates Degradation of SERCA2a in Vascular Smooth Muscle Cells |
| Q39308907 | A designed zinc-finger transcriptional repressor of phospholamban improves function of the failing heart. |
| Q44737488 | A minimally invasive approach for efficient gene delivery to rodent hearts |
| Q24301857 | A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. |
| Q27023389 | A network-oriented perspective on cardiac calcium signaling |
| Q35315333 | A new model of congestive heart failure in rats |
| Q35132004 | A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum. |
| Q35812855 | A novel human R25C-phospholamban mutation is associated with super-inhibition of calcium cycling and ventricular arrhythmia |
| Q57799740 | A role for calcium in resistin transcriptional activation in diabetic hearts |
| Q34248473 | AAV6.βARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model |
| Q37682472 | Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling |
| Q35061110 | Active inhibitor-1 maintains protein hyper-phosphorylation in aging hearts and halts remodeling in failing hearts |
| Q44648728 | Additive improvement of left ventricular remodeling and neurohormonal activation by aldosterone receptor blockade with eplerenone and ACE inhibition in rats with myocardial infarction |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q33535920 | Alpha1A-adrenergic receptor-directed autoimmunity induces left ventricular damage and diastolic dysfunction in rats |
| Q33683757 | Altered intracellular Ca2+ handling in heart failure |
| Q35116100 | Altered myocardial calcium cycling and energetics in heart failure--a rational approach for disease treatment |
| Q36837270 | Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy |
| Q36313661 | Ameliorated stress related proteins are associated with improved cardiac function by sarcoplasmic reticulum calcium ATPase gene transfer in heart failure |
| Q44071491 | Augmentation of left ventricular mechanics by recirculation-mediated AAV2/1-SERCA2a gene delivery in experimental heart failure |
| Q51869172 | Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases. |
| Q37358922 | Beta-adrenergic stimulation and myocardial function in the failing heart |
| Q28582056 | CXCR4 modulates contractility in adult cardiac myocytes |
| Q39493909 | Ca2+ cycling and new therapeutic approaches for heart failure |
| Q34195822 | Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): a phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure |
| Q37915240 | Calcium cycling proteins and their association with heart failure |
| Q27026716 | Calcium mishandling in diastolic dysfunction: mechanisms and potential therapies |
| Q37364786 | Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. |
| Q38916981 | Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial |
| Q34409721 | Cardiac Gene Therapy |
| Q46952259 | Cardiac contractility modulation therapy in advanced systolic heart failure |
| Q44068487 | Cardiac dysfunction in terms of left ventricular mechanical work and energetics in hypothyroid rats |
| Q38820937 | Cardiac gene therapy: are we there yet? |
| Q45883073 | Cardiac gene therapy: kick-starting calcium cycling in rats |
| Q37076149 | Cardiac surgical delivery of the sarcoplasmic reticulum calcium ATPase rescues myocytes in ischemic heart failure |
| Q40114591 | Cardiac-directed parvalbumin transgene expression in mice shows marked heart rate dependence of delayed Ca2+ buffering action |
| Q34191737 | Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade |
| Q36441343 | Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. |
| Q45888008 | Chronic suppression of heart-failure progression by a pseudophosphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery |
| Q90589875 | Cisd2 is essential to delaying cardiac aging and to maintaining heart functions |
| Q34695565 | Compromised myocardial energetics in hypertrophied mouse hearts diminish the beneficial effect of overexpressing SERCA2a |
| Q64377359 | Contractile effects of adenovirally-mediated increases in SERCA2a activity: a comparison between adult rat and rabbit ventricular myocytes |
| Q52604700 | Correcting Calcium Dysregulation in Chronic Heart Failure Using SERCA2a Gene Therapy. |
| Q37299072 | Designing heart performance by gene transfer. |
| Q28395852 | Diabetic cardiomyopathy: signaling defects and therapeutic approaches |
| Q36724656 | Drug discovery for heart failure: a new era or the end of the pipeline? |
| Q89782554 | Dysregulation of Calcium Handling in Duchenne Muscular Dystrophy-Associated Dilated Cardiomyopathy: Mechanisms and Experimental Therapeutic Strategies |
| Q92982557 | Effect of Valsartan on Sarcoplasmic Reticulum Ca2+-ATPase Pump of the Left Ventricular Myocardium in Rats with Heart Failure with Preserved Ejection Fraction |
| Q37685861 | Effect of bortezomib on the efficacy of AAV9.SERCA2a treatment to preserve cardiac function in a rat pressure-overload model of heart failure. |
| Q38844989 | Effect of intracoronary administration of AAV1/SERCA2a on ventricular remodelling in patients with advanced systolic heart failure: results from the AGENT-HF randomized phase 2 trial |
| Q45865447 | Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo |
| Q45145605 | Electric pulses augment reporter gene expression in the beating heart |
| Q37138937 | Endothelin downregulates SERCA2 gene and protein expression in adult rat ventricular myocytes: regulation by pertussis toxin-sensitive Gi protein and cAMP. |
| Q35602060 | Energy metabolism in heart failure |
| Q58612995 | Enhancing atrial specific gene expression using a calsequestrin cis-regulatory module 4 with a sarcolipin promoter |
| Q83554578 | Evaluation of left ventricular mechanical work and energetics of normal hearts in SERCA2a transgenic rats |
| Q36893596 | Excitation-contraction coupling and mitochondrial energetics |
| Q38303620 | Experimental models of inherited cardiomyopathy and its therapeutics |
| Q38025012 | Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function |
| Q35873759 | Gene delivery approaches to heart failure treatment |
| Q34130135 | Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation |
| Q26863362 | Gene delivery technologies for cardiac applications |
| Q33489603 | Gene remodeling in type 2 diabetic cardiomyopathy and its phenotypic rescue with SERCA2a |
| Q45857145 | Gene therapy for diabetic cardiomyopathy: a new approach for a difficult problem |
| Q35791499 | Gene therapy for heart failure |
| Q45856609 | Gene therapy for heart failure: an investigational treatment that is coming of age. |
| Q45871159 | Gene therapy for heart failure: time to go back to the drawing board |
| Q37857290 | Gene therapy for ischemic heart disease. |
| Q35218719 | Gene therapy for the treatment of heart failure--calcium signaling |
| Q36944623 | Gene therapy in heart failure |
| Q36786243 | Gene therapy in the treatment of heart failure |
| Q27022444 | Gene therapy targets in heart failure: the path to translation |
| Q36698991 | Gene transfer for congestive heart failure: update 2013. |
| Q35724614 | Gene transfer in cardiac myocytes. |
| Q35106501 | Genetic editing of dysfunctional myocardium |
| Q36050486 | Genetic maneuvers to ameliorate ventricular function in heart failure: therapeutic potential and future implications |
| Q45032167 | Genetic manipulation of calcium-handling proteins in cardiac myocytes. I. Experimental studies |
| Q38099580 | Genetic prediction of heart failure incidence, prognosis and beta-blocker response |
| Q37204272 | HNO enhances SERCA2a activity and cardiomyocyte function by promoting redox-dependent phospholamban oligomerization |
| Q33605156 | Heart failure management: the present and the future |
| Q45863016 | Highly efficient and specific modulation of cardiac calcium homeostasis by adenovector-derived short hairpin RNA targeting phospholamban |
| Q24307062 | Histidine-rich Ca-binding protein interacts with sarcoplasmic reticulum Ca-ATPase |
| Q57823807 | Human Cardiac Gene Therapy |
| Q36114228 | Immunosuppression decreases inflammation and increases AAV6-hSERCA2a-mediated SERCA2a expression |
| Q34931636 | Integration of pathways that signal cardiac growth with modulation of myofilament activity |
| Q42527073 | Interaction between increased SERCA2a activity and beta -adrenoceptor stimulation in adult rabbit myocytes. |
| Q45886178 | Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure |
| Q97569409 | Investigation of the safety and feasibility of AAV1/SERCA2a gene transfer in patients with chronic heart failure supported with a left ventricular assist device - the SERCA-LVAD TRIAL |
| Q37636547 | Left ventricular diastolic dysfunction of the cardiac surgery patient; a point of view for the cardiac surgeon and cardio-anesthesiologist |
| Q46570729 | Left ventricular mechanical and energetic changes in long-term isoproterenol-induced hypertrophied hearts of SERCA2a transgenic rats |
| Q38292060 | Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats |
| Q37038822 | Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo |
| Q92398990 | Loss of SRSF3 in Cardiomyocytes Leads to Decapping of Contraction-Related mRNAs and Severe Systolic Dysfunction |
| Q46964433 | Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer |
| Q37833553 | Merits of non-invasive rat models of left ventricular heart failure. |
| Q26823061 | Model-specific selection of molecular targets for heart failure gene therapy |
| Q36480080 | Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy |
| Q37099714 | Molecular basis of diastolic dysfunction. |
| Q34803109 | Molecular medicine for the cardiac surgeon |
| Q37709194 | Myostatin regulates tissue potency and cardiac calcium-handling proteins |
| Q43010140 | NADPH oxidase inhibition ameliorates cardiac dysfunction in rabbits with heart failure |
| Q34313853 | Neonatal gene transfer of Serca2a delays onset of hypertrophic remodeling and improves function in familial hypertrophic cardiomyopathy |
| Q38966607 | Noninvasive stratification of postinfarction rats based on the degree of cardiac dysfunction using magnetic resonance imaging and echocardiography |
| Q37436743 | Orphan targets for reperfusion injury. |
| Q37691385 | Overexpression of Sarcoendoplasmic Reticulum Calcium ATPase 2a Promotes Cardiac Sympathetic Neurotransmission via Abnormal Endoplasmic Reticulum and Mitochondria Ca2+ Regulation. |
| Q54396560 | Percutaneous intracoronary delivery of SERCA gene increases myocardial function: a tissue Doppler imaging echocardiographic study. |
| Q38994570 | Peroxisome proliferator-activated receptor-α expression induces alterations in cardiac myofilaments in a pressure-overload model of hypertrophy |
| Q46647997 | Phenylephrine hypertrophy, Ca2+-ATPase (SERCA2), and Ca2+ signaling in neonatal rat cardiac myocytes |
| Q24337525 | Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ current |
| Q36228624 | Phospholamban Ablation Using CRISPR/Cas9 System Improves Mortality in a Murine Heart Failure Model |
| Q35032742 | Phospholamban interactome in cardiac contractility and survival: A new vision of an old friend |
| Q35167969 | Phospholamban: a crucial regulator of cardiac contractility |
| Q36951008 | Plasticity of surface structures and β(2)-adrenergic receptor localization in failing ventricular cardiomyocytes during recovery from heart failure |
| Q30383732 | Post-translational Modifications in Heart Failure: Small Changes, Big Impact |
| Q46921446 | Preservation of mechanical and energetic function after adenoviral gene transfer in normal rat hearts |
| Q37734294 | Proinflammatory cytokines in heart failure: double-edged swords |
| Q39356341 | Promise of adeno-associated virus as a gene therapy vector for cardiovascular diseases |
| Q45868599 | Pulmonary venous hypertension and mechanical strain stimulate monocyte chemoattractant protein-1 release and structural remodelling of the lung in human and rodent chronic heart failure models |
| Q38584364 | Recent Developments in Heart Failure |
| Q45879221 | Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals |
| Q35793542 | Recruitment of NADH shuttling in pressure-overloaded and hypertrophic rat hearts |
| Q37821376 | Regenerative therapies in electrophysiology and pacing: introducing the next steps |
| Q37608521 | Regulation of myocardial SERCA2a expression in ventricular hypertrophy and heart failure |
| Q37088473 | Remodeling of calcium handling in human heart failure |
| Q39747918 | Rescue of cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular failure in genetic hypertrophy |
| Q33787794 | Rescue of familial cardiomyopathies by modifications at the level of sarcomere and Ca2+ fluxes |
| Q34757960 | Rescuing the failing heart by targeted gene transfer |
| Q35933316 | Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins |
| Q91755231 | Role of SIRT1 in Modulating Acetylation of the Sarco-Endoplasmic Reticulum Ca2+-ATPase in Heart Failure |
| Q37054922 | Role of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation |
| Q46330392 | SERCA control of cell death and survival |
| Q33636306 | SERCA1 expression enhances the metabolic efficiency of improved contractility in post-ischemic heart |
| Q40910862 | SERCA2a gene therapy for heart failure: ready for primetime? |
| Q37418216 | SERCA2a gene therapy in heart failure: an anti-arrhythmic positive inotrope. |
| Q35057816 | SERCA2a gene transfer decreases sarcoplasmic reticulum calcium leak and reduces ventricular arrhythmias in a model of chronic heart failure |
| Q34025110 | SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells |
| Q42480285 | SERCA2a gene transfer prevents intimal proliferation in an organ culture of human internal mammary artery |
| Q36476041 | SERCA2a in heart failure: role and therapeutic prospects |
| Q37676218 | Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure |
| Q38016716 | Sarcoplasmic reticulum and calcium cycling targeting by gene therapy |
| Q28658055 | Small and large animal models in cardiac contraction research: advantages and disadvantages |
| Q37457469 | TSH inhibits SERCA2a and the PKA/PLN pathway in rat cardiomyocytes |
| Q37878086 | Targeted gene therapy for the treatment of heart failure |
| Q53580927 | Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts. |
| Q35037546 | Targeting calcium cycling proteins in heart failure through gene transfer |
| Q35763705 | Targeting cardiomyocyte Ca2+ homeostasis in heart failure |
| Q34074819 | Targeting phospholamban by gene transfer in human heart failure |
| Q58722435 | Targeting protein-protein interactions for therapeutic discovery via FRET-based high-throughput screening in living cells |
| Q35095401 | Targeting signaling pathways in heart failure by gene transfer |
| Q42162747 | Tead1 is required for maintaining adult cardiomyocyte function, and its loss results in lethal dilated cardiomyopathy. |
| Q36570908 | The Ca2+ ATPase of cardiac sarcoplasmic reticulum: Physiological role and relevance to diseases |
| Q57288455 | The DWORF micropeptide enhances contractility and prevents heart failure in a mouse model of dilated cardiomyopathy |
| Q37229784 | The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases |
| Q34968383 | The challenge of molecular medicine: complexity versus Occam's razor |
| Q35192551 | The molecular basis of myocardial hypertrophy and heart failure |
| Q42501302 | The onset of left ventricular diastolic dysfunction in SHR rats is not related to hypertrophy or hypertension |
| Q58123133 | The potential use of AKAP18δ as a drug target in heart failure patients |
| Q47319449 | Transcoronary gene transfer of SERCA2a increases coronary blood flow and decreases cardiomyocyte size in a type 2 diabetic rat model |
| Q92327319 | Treatment of chronic heart failure in the 21st century: A new era of biomedical engineering has come |
| Q40199219 | Treatment of heart failure by calcium cycling gene therapy |
| Q37793527 | What Causes a Broken Heart—Molecular Insights into Heart Failure |
| Q36099938 | What makes the mitochondria a killer? Can we condition them to be less destructive? |
| Q43703662 | microRNA122-regulated transgene expression increases specificity of cardiac gene transfer upon intravenous delivery of AAV9 vectors |
Search more.